Stoicănescu Dorina, Andreescu Nicoleta, Belengeanu Alina, Meszaros Noemi, Cornianu Mărioara
Department of Microscopic Morphology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania;
Rom J Morphol Embryol. 2013;54(4):1107-13.
Identification of the genes involved in tumor initiation and progression has led to development of new markers and generated targets for new drugs. This study aimed to evaluate p53 and HER-2/neu genes status of and their protein products in oral cancer patients. Tumor specimens from 116 cases diagnosed with oral squamous cell carcinoma were analyzed. P53 and HER-2/neu immunoreactivity were studied. FISH analysis was performed to elucidate p53 and HER-2/neu gene status. Male cases represented 84% of the group. The majority of cases were between 51-60 years and moderately differentiated oral carcinoma had an incidence of 58.6%. Thirty-four cases showed p53 overexpression, negative immunoreaction was observed in 16.37% of cases. 66.38% of cases had p53 deletion, with an increased rate observed in neoplasms of the tongue. Immunohistochemical analysis of HER-2/neu receptor protein revealed that 76.72% were negative, 5.17% had weak immunostaining, 14.65% had +2 score, the others had +3 score. 24.1% of cases were analyzed using FISH technique, of which 25% were without amplification, but with polysomy for chromosome 17. 18.1% of total cases were amplified, with the rate HER-2/neu:CEP17 higher than 2. Of the 77 cases with a single p53 allele, 20 associated HER-2/neu amplification, 31 had positive anti-HER-2/neu immunoreaction, but did not have HER-2/neu:CEP17 rate >2. There was a significant association between HER-2/neu amplification and deletion of a p53 allele. These results could justify more extensive research to assess p53 and HER-2/neu gene status as significant prognostic factors in oral cancers.
对参与肿瘤起始和进展的基因的鉴定已促成新标志物的开发，并为新药生成了靶点。本研究旨在评估口腔癌患者中p53和HER-2/neu基因状态及其蛋白产物。分析了116例诊断为口腔鳞状细胞癌的肿瘤标本。研究了p53和HER-2/neu免疫反应性。进行荧光原位杂交（FISH）分析以阐明p53和HER-2/neu基因状态。男性病例占该组的84%。大多数病例年龄在51至60岁之间，中度分化的口腔癌发病率为58.6%。34例显示p53过表达，16.37%的病例观察到阴性免疫反应。66.38%的病例存在p53缺失，在舌部肿瘤中观察到增加的比例。HER-2/neu受体蛋白的免疫组织化学分析显示，76.72%为阴性，5.17%有弱免疫染色，14.65%评分为+2，其他评分为+3。24.1%的病例使用FISH技术进行分析，其中25%无扩增，但17号染色体多体。18.1%的总病例有扩增，HER-2/neu:CEP-17率高于2。在77例具有单个p53等位基因的病例中，20例伴有HER-2/neu扩增，31例抗HER-2/neu免疫反应阳性，但HER-2/neu:CEP-17率>2。HER-2/neu扩增与p53等位基因缺失之间存在显著关联。这些结果可为更广泛的研究提供依据，以评估p53和HER-2/neu基因状态作为口腔癌重要预后因素的情况。
